Quantcast

United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.

Research paper by F F Davies, C C Morris, J J Bird, G G Cook, C C Williams, J J Tighe, J J Cavenagh, J J Behrens, S S Schey, G G Morgan,

Indexed on: 20 Nov '08Published on: 20 Nov '08Published in: International Journal of Laboratory Hematology



Abstract

Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro. Phase II clinical trials have demonstrated lenalidomide in combination with dexamethasone is effective for the treatment of both relapsed refractory myeloma and newly diagnosed patients. Two large phase III studies comparing lenalidomide and dexamethasone to dexamethasone alone in relapsed patients showed superiority in response, progression free and overall survival. It is administered orally for 21 days in a 28 day cycle. Side effects are manageable and include neutropenia and venous thrombotic events. It is currently approved, in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy. Studies in front line patients and with other drug combinations are ongoing. Given the strength of this data the UK Myeloma Forum believe that lenalidomide in combination with dexamethasone should be available for prescription by UK haematologists according to its licensed indication in patients with relapsed myeloma.